Adalimumab as a cause of kidney injury in patients with Crohn's disease.
Adalimumab
Crohn’s disease
Drug reaction
Kidney injury
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
01
01
2024
accepted:
27
02
2024
revised:
26
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
Adalimumab (ADM) is a recombinant human monoclonal antibody (anti-TNFα) used to treat inflammatory bowel diseases. It can cause kidney injury (KI). We describe two pediatric patients with Crohn's disease (CD) in whom ADM therapy was associated with kidney injury (KI). The drug was discontinued in both cases. For the first patient, changes were irreversible despite intensive glucocorticosteroid (GCS) therapy. For the second patient, discontinuation of ADM led to an improvement in kidney function. Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.
Identifiants
pubmed: 38456916
doi: 10.1007/s00467-024-06338-0
pii: 10.1007/s00467-024-06338-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Sandys V, Moloney B, Lane L, Qazi J, Doyle B, Barry M, Leavey S, Conlon P (2018) Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J 11:219–221. https://doi.org/10.1093/ckj/sfx104
doi: 10.1093/ckj/sfx104
pubmed: 29644062
Graziano F, Busè M, Cassata N, Lentini VL, Citrano M (2022) IgA nephropathy in a child: Crohn’s disease-associated or adalimumab induced? Curr Med Res Opin 38:139–143. https://doi.org/10.1080/03007995.2021.2015155
doi: 10.1080/03007995.2021.2015155
pubmed: 34866503
Chen TJ, Yang YF, Huang PH, Lin HH, Huang CC (2010) Permanent renal loss following tumor necrosis factor α antagonists for arthritis. Rheumatol Int 30:1077–1079. https://doi.org/10.1007/s00296-009-1016-2
doi: 10.1007/s00296-009-1016-2
pubmed: 19536543
Usui J, Salvatore SP, Yamagata K, Seshan SV (2023) Clinicopathologic spectrum of renal lesions following anti-TNF-α inhibitor therapy: a single center experience. Kidney360 4:363–373. https://doi.org/10.34067/KID.0000000000000063
doi: 10.34067/KID.0000000000000063
Tamura H (2023) IgA nephropathy associated with Crohn’s disease. World J Methodol 13:67–78. https://doi.org/10.5662/wjm.v13.i3.67
doi: 10.5662/wjm.v13.i3.67
pubmed: 37456980
pmcid: 10348078